Phase 2c: Expedited Development for All 2017-10-03T21:37:36+00:00

Project Description

Only a limited percentage of drugs receive access to accelerated development pathways. Read this white paper to learn about a proposed approach to expanding access to accelerated development pathways to a much greater range of investigation products while maintaining attention to patient safety.

Download PDF
SUBMIT RFP